Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer

(MedPage Today) -- NEW ORLEANS -- More than 60% of patients with unresectable gastric/gastroesophageal junction (GEJ) cancer responded to the combination of a CD39 inhibitor and chemoimmunotherapy, a small clinical trial showed. The data showed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news